Prognostic Importance of Comorbidity and the Association Between Comorbidity and p16 in Oropharyngeal Squamous Cell Carcinoma | Head and Neck Cancer | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
1.
Chaturvedi  AK, Engels  EA, Anderson  WF, Gillison  ML.  Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.  J Clin Oncol. 2008;26(4):612-619.PubMedGoogle ScholarCrossref
2.
Chaturvedi  AK, Engels  EA, Pfeiffer  RM,  et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.  J Clin Oncol. 2011;29(32):4294-4301.PubMedGoogle ScholarCrossref
3.
Cole  L, Polfus  L, Peters  ES.  Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995-2005.  PLoS One. 2012;7(3):e32657.PubMedGoogle ScholarCrossref
4.
Stein  AP, Saha  S, Yu  M, Kimple  RJ, Lambert  PF.  Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time.  Chem Res Toxicol. 2014;27(4):462-469.PubMedGoogle ScholarCrossref
5.
Hess  CB, Rash  DL, Daly  ME,  et al.  Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.  JAMA Otolaryngol Head Neck Surg. 2014;140(4):312-316.PubMedGoogle ScholarCrossref
6.
Gillison  ML, D’Souza  G, Westra  W,  et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.  J Natl Cancer Inst. 2008;100(6):407-420.PubMedGoogle ScholarCrossref
7.
Gillison  ML, Koch  WM, Capone  RB,  et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.  J Natl Cancer Inst. 2000;92(9):709-720.PubMedGoogle ScholarCrossref
8.
Andl  T, Kahn  T, Pfuhl  A,  et al.  Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control.  Cancer Res. 1998;58(1):5-13.PubMedGoogle Scholar
9.
Fakhry  C, Westra  WH, Li  S,  et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.  J Natl Cancer Inst. 2008;100(4):261-269.PubMedGoogle ScholarCrossref
10.
Ragin  CC, Taioli  E.  Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.  Int J Cancer. 2007;121(8):1813-1820.PubMedGoogle ScholarCrossref
11.
Ang  KK, Harris  J, Wheeler  R,  et al.  Human papillomavirus and survival of patients with oropharyngeal cancer.  N Engl J Med. 2010;363(1):24-35.PubMedGoogle ScholarCrossref
12.
Rischin  D, Young  RJ, Fisher  R,  et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.  J Clin Oncol. 2010;28(27):4142-4148.PubMedGoogle ScholarCrossref
13.
Klussmann  JP, Gültekin  E, Weissenborn  SJ,  et al.  Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus.  Am J Pathol. 2003;162(3):747-753.PubMedGoogle ScholarCrossref
14.
Wang  H, Sun  R, Lin  H, Hu  WH.  P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects.  Cancer Sci. 2013;104(12):1553-1559.PubMedGoogle ScholarCrossref
15.
Sinha  P, Kallogjeri  D, Piccirillo  JF.  Assessment of comorbidities in surgical oncology outcomes.  J Surg Oncol. 2014;110(5):629-635.PubMedGoogle ScholarCrossref
16.
Derks  W, de Leeuw  RJ, Hordijk  GJ.  Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survival.  Curr Opin Otolaryngol Head Neck Surg. 2005;13(2):92-96.PubMedGoogle ScholarCrossref
17.
Piccirillo  JF, Tierney  RM, Costas  I, Grove  L, Spitznagel  EL  Jr.  Prognostic importance of comorbidity in a hospital-based cancer registry.  JAMA. 2004;291(20):2441-2447.PubMedGoogle ScholarCrossref
18.
Iversen  LH, Nørgaard  M, Jacobsen  J, Laurberg  S, Sørensen  HT.  The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006: a population-based cohort study.  Dis Colon Rectum. 2009;52(1):71-78.PubMedGoogle ScholarCrossref
19.
Patnaik  JL, Byers  T, Diguiseppi  C, Denberg  TD, Dabelea  D.  The influence of comorbidities on overall survival among older women diagnosed with breast cancer.  J Natl Cancer Inst. 2011;103(14):1101-1111.PubMedGoogle ScholarCrossref
20.
Land  LH, Dalton  SO, Jensen  M-B, Ewertz  M.  Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008.  Breast Cancer Res Treat. 2012;131(3):1013-1020.PubMedGoogle ScholarCrossref
21.
Lüchtenborg  M, Jakobsen  E, Krasnik  M, Linklater  KM, Mellemgaard  A, Møller  H.  The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients.  Eur J Cancer. 2012;48(18):3386-3395.PubMedGoogle ScholarCrossref
22.
Wang  C-Y, Lin  Y-S, Tzao  C,  et al.  Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection.  Eur J Cardiothorac Surg. 2007;32(6):877-881.PubMedGoogle ScholarCrossref
23.
Peipert  JF, Wells  CK, Schwartz  PE, Feinstein  AR.  Prognostic value of clinical variables in invasive cervical cancer.  Obstet Gynecol. 1994;84(5):746-751.PubMedGoogle Scholar
24.
Paleri  V, Wight  RG, Davies  GR.  Impact of comorbidity on the outcome of laryngeal squamous cancer.  Head Neck. 2003;25(12):1019-1026.PubMedGoogle ScholarCrossref
25.
Singh  B, Bhaya  M, Zimbler  M,  et al.  Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma.  Head Neck. 1998;20(1):1-7.PubMedGoogle ScholarCrossref
26.
Habbous  S, Harland  LT, La Delfa  A,  et al.  Comorbidity and prognosis in head and neck cancers: differences by subsite, stage, and human papillomavirus status.  Head Neck. 2014;36(6):802-810.PubMedGoogle ScholarCrossref
27.
Yung  KC, Piccirillo  JF.  The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer.  Arch Otolaryngol Head Neck Surg. 2008;134(10):1045-1049.PubMedGoogle ScholarCrossref
28.
Piccirillo  JF.  Importance of comorbidity in head and neck cancer.  Laryngoscope. 2000;110(4):593-602.PubMedGoogle ScholarCrossref
29.
Rietbergen  MM, Brakenhoff  RH, Bloemena  E,  et al.  Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment de-escalation trials.  Ann Oncol. 2013;24(11):2740-2745.PubMedGoogle ScholarCrossref
30.
Rios Velazquez  E, Hoebers  F, Aerts  HJ,  et al.  Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging.  Radiother Oncol. 2014;113(3):324-330.PubMedGoogle ScholarCrossref
31.
Haughey  BH, Sinha  P.  Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.  Laryngoscope. 2012;122(S2)(suppl 2):S13-S33.PubMedGoogle ScholarCrossref
32.
Gourin  CG, Podolsky  RH.  Racial disparities in patients with head and neck squamous cell carcinoma.  Laryngoscope. 2006;116(7):1093-1106.PubMedGoogle ScholarCrossref
33.
Edge  SB, Byrd  DR, Compton  CC, Fritz  AG, Greene  FL, Trotti  A  III.  AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
34.
Yasui  T, Morii  E, Yamamoto  Y,  et al.  Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin.  PLoS One. 2014;9(4):e95364.PubMedGoogle ScholarCrossref
35.
Zengel  P, Assmann  G, Mollenhauer  M,  et al.  Cancer of unknown primary originating from oropharyngeal carcinomas are strongly correlated to HPV positivity.  Virchows Arch. 2012;461(3):283-290.PubMedGoogle ScholarCrossref
36.
Begum  S, Gillison  ML, Ansari-Lari  MA, Shah  K, Westra  WH.  Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.  Clin Cancer Res. 2003;9(17):6469-6475.PubMedGoogle Scholar
37.
Lewis  JS  Jr, Carpenter  DH, Thorstad  WL, Zhang  Q, Haughey  BH.  Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma.  Mod Pathol. 2011;24(11):1413-1420.PubMedGoogle ScholarCrossref
38.
Harrell  FE  Jr, Lee  KL, Califf  RM, Pryor  DB, Rosati  RA.  Regression modelling strategies for improved prognostic prediction.  Stat Med. 1984;3(2):143-152.PubMedGoogle ScholarCrossref
39.
Charlson  ME, Pompei  P, Ales  KL, MacKenzie  CR.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chronic Dis. 1987;40(5):373-383.PubMedGoogle ScholarCrossref
40.
Huang  SH, Xu  W, Waldron  J,  et al.  Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.  J Clin Oncol. 2015;33(8):836-845.PubMedGoogle ScholarCrossref
41.
Masterson  L, Moualed  D, Liu  ZW,  et al.  De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.  Eur J Cancer. 2014;50(15):2636-2648.PubMedGoogle ScholarCrossref
Original Investigation
June 2016

Prognostic Importance of Comorbidity and the Association Between Comorbidity and p16 in Oropharyngeal Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Otolaryngology–Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri
  • 2Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri
  • 3Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
  • 4Editor, JAMA Otolaryngology–Head & Neck Surgery
JAMA Otolaryngol Head Neck Surg. 2016;142(6):568-575. doi:10.1001/jamaoto.2016.0347
Abstract

Importance  Comorbidity affects the prognosis of patients with cancer through the direct effects of the comorbid illness and by influencing the patients’ ability to tolerate treatment and mount a host response. However, the prognostic importance of comorbidity in oropharyngeal squamous cell carcinoma is not well characterized in the era of human papillomavirus infection.

Objective  To determine the prognostic importance of comorbidity in both p16-positive and p16-negative oropharyngeal squamous cell carcinoma and to explore the relationship between comorbidity and p16.

Design, Setting, and Participants  Retrospective cohort study of 305 patients at a single tertiary referral center diagnosed as having oropharyngeal squamous cell carcinoma between June 1996 and June 2010, but without a history of head and neck cancer or distant metastasis at time of diagnosis. The data were analyzed from August 1, 2014, through April 30, 2015.

Exposures  Patients were grouped according to p16 status.

Main Outcomes and Measures  Overall survival, defined as the time from diagnosis to death from any cause. Disease-free survival, defined as the time from diagnosis to either death from any cause or the first documented local, regional, or distant recurrence.

Results  Of the 305 patients who met eligibility criteria, 230 were p16-positive, 70 were p16-negative, and 5 were not evaluable for p16 status. The final cohort of 300 patients had a mean (SD) age of 56.3 (9.3) years and 262 (87%) were male. In Kaplan-Meier analysis, the 5-year overall survival rates were 71% (95% CI, 65%-76%) for 232 patients with no comorbidity to mild comorbidity and 49% (95% CI, 36%-61%) for 63 patients with moderate to severe comorbidity. In multivariate Cox proportional hazards analysis, moderate to severe comorbidity was associated with an increased risk of death from any cause (adjusted hazards ratio [aHR], 1.52 [95% CI, 0.99-2.32]) and increased risk of death or recurrence (aHR, 1.71 [95% CI, 1.13-2.59]). After stratifying by p16 status and controlling for other variables, moderate to severe comorbidity was significantly associated with increased risk of death from any cause among p16-negative patients (aHR, 1.90 [95% CI, 1.03-3.50]) but not among p16-positive patients (aHR, 1.11 [95% CI, 0.61-2.02]).

Conclusions and Relevance  Comorbidity is important to consider when assessing the prognosis of patients with oropharyngeal squamous cell carcinoma and is of greater prognostic value in p16-negative than p16-positive cancer.

×